Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH)

David J Araten, MD, Rosario Notaro, MD, Nancy A Kernan, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Trudy N Small, M.D, Andromachi Scaradavou, MD, Heather Magnan, MD, Susan E Prockop, MD, Sara Chaffee, MD, Jason Gonsky, MD, PhD, Raymond Thertulien, MD, PhD, Roberto Tarquini, MD, Lucio Luzzatto, MD

Blood (2010) 116 (21): 4239.

https://doi.org/10.1182/blood.V116.21.4239.4239

Published: 2010

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

A Comparative Investigation of Therapeutic Approaches for Primary Prostate Cancer and Risk of Acute Myeloid Leukemia.

Rohit P. Ojha, MPH, Raymond Thertulien, MD, PhD, Deepak Prabhakar, MD, MPH, Yi Zhou, MS, Lori A. Fischbach, PhD, MPH

Blood (2007) 110 (11): 1816.

https://doi.org/10.1182/blood.V110.11.1816.1816

Published: 2007

Journal Articles

Population-Based Risk Assessment for Multiple Myeloma: A Novel Approach for Identifying Potential Environmental Associations.

Rohit P. Ojha, MPH, Martha M. Phillips, PhD, MPH, MBA, Raymond Thertulien, MD, PhD

Blood (2005) 106 (11): 5058.

https://doi.org/10.1182/blood.V106.11.5058.5058

Published: 2005

Journal Articles

Copper Deficiency Secondary to Bariatric Surgery Mimicking Myelodysplasia.

Vaishali R. Doshi, MD, Raymond Thertulien, M.D, PhD

Blood (2005) 106 (11): 4930.

https://doi.org/10.1182/blood.V106.11.4930.4930

Published: 2005

Journal Articles

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Athanasios Fassas, MD, Erik Rasmussen, Raymond Thertulien, MD, PhD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 1480.

https://doi.org/10.1182/blood.V104.11.1480.1480

Published: 2004

Journal Articles

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampalamo Talamo, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Frits van Rhee, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 929.

https://doi.org/10.1182/blood.V104.11.929.929

Published: 2004

Journal Articles

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Athanasios Fassas, MD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, MD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 932.

https://doi.org/10.1182/blood.V104.11.932.932

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

Journal Articles

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, MD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 940.

https://doi.org/10.1182/blood.V104.11.940.940

Published: 2004

Journal Articles

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Blood (2004) 104 (11): 784.

https://doi.org/10.1182/blood.V104.11.784.784

Published: 2004

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 4935.

https://doi.org/10.1182/blood.V104.11.4935.4935

Published: 2004

Journal Articles

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD,MS, Monica L. Grazziutti, MD, Sabitha Rajan, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 1158.

https://doi.org/10.1182/blood.V104.11.1158.1158

Published: 2004

Journal Articles

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Dong Li, MD, MS, Marisa H. Miceli, MD, Athanasios Fassas, MD, Raymond Thertulien, MD, PhD, Sabitha Rajan, Fariba Saghafifar, MD, Guido J. Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 1159.

https://doi.org/10.1182/blood.V104.11.1159.1159

Published: 2004

NARROW

Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH)

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

A Comparative Investigation of Therapeutic Approaches for Primary Prostate Cancer and Risk of Acute Myeloid Leukemia.

Population-Based Risk Assessment for Multiple Myeloma: A Novel Approach for Identifying Potential Environmental Associations.

Copper Deficiency Secondary to Bariatric Surgery Mimicking Myelodysplasia.

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only